Loading…
Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility Part 1
The reported selective serotonin Re-uptake Inhibitor (SSRI) litoxetine was used as the starting point in the design of a range of potent, selective SSRIs with high ease of synthetic accessibility. The reported selective serotonin Re-uptake Inhibitor Litoxetine was used as the starting point in the d...
Saved in:
| Published in: | Bioorganic & medicinal chemistry letters 2009-04, Vol.19 (8), p.2329-2332 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c415t-a2d15162d695aa7606158d09d3c8b71244e53efa2446de4242fe0ec82497ab693 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c415t-a2d15162d695aa7606158d09d3c8b71244e53efa2446de4242fe0ec82497ab693 |
| container_end_page | 2332 |
| container_issue | 8 |
| container_start_page | 2329 |
| container_title | Bioorganic & medicinal chemistry letters |
| container_volume | 19 |
| creator | Andrews, Mark Brown, Alan Chiva, Jean-Yves Fradet, David Gordon, David Lansdell, Mark MacKenny, Malcolm |
| description | The reported selective serotonin Re-uptake Inhibitor (SSRI) litoxetine was used as the starting point in the design of a range of potent, selective SSRIs with high ease of synthetic accessibility.
The reported selective serotonin Re-uptake Inhibitor Litoxetine was used as the starting point in the design of a range of potential SSRIs with high ease of synthetic accessibility. Preparation and subsequent optimization yielded a range of potent and highly selective SSRIs. |
| doi_str_mv | 10.1016/j.bmcl.2009.02.054 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67111485</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960894X0900208X</els_id><sourcerecordid>20531701</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-a2d15162d695aa7606158d09d3c8b71244e53efa2446de4242fe0ec82497ab693</originalsourceid><addsrcrecordid>eNqFkbGO1DAQhi0E4vYOXoACuYEuweM4TiLRoIMDpJOgAInOcpzJZZYkXmzvoeXp8WpX0EE1f_HNaPR_jD0DUYIA_Wpb9oubSylEVwpZilo9YBtQWhWVEvVDthGdFkXbqW8X7DLGrRCghFKP2QV0spXQqA2b32Kku5XbdeB-l2ihXzaRX7kfecQZXaJ7zCn45FdaecBiv0v2O3JaJ-op-RD5T0oTn-hu4vGwpgkTOW6dwxgzMVM68M82JA5P2KPRzhGfnucV-3rz7sv1h-L20_uP129uC6egToWVA9Sg5aC72tpGCw11O4huqFzbNyCVwrrC0eagB1RSyREFulaqrrG97qor9vJ0dxf8jz3GZBaKDufZruj30egGAFRb_xeUoq6gEZBBeQJd8DEGHM0u0GLDwYAwRxlma44yzFGGEdJkGXnp-fn6vl9w-Ltybj8DL86Ajc7OY7Cro_iHk1B10ILM3OsTh7m0e8JgoiNcHQ4UsiEzePrXH78BRzqoyg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20531701</pqid></control><display><type>article</type><title>Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility Part 1</title><source>Elsevier</source><creator>Andrews, Mark ; Brown, Alan ; Chiva, Jean-Yves ; Fradet, David ; Gordon, David ; Lansdell, Mark ; MacKenny, Malcolm</creator><creatorcontrib>Andrews, Mark ; Brown, Alan ; Chiva, Jean-Yves ; Fradet, David ; Gordon, David ; Lansdell, Mark ; MacKenny, Malcolm</creatorcontrib><description>The reported selective serotonin Re-uptake Inhibitor (SSRI) litoxetine was used as the starting point in the design of a range of potent, selective SSRIs with high ease of synthetic accessibility.
The reported selective serotonin Re-uptake Inhibitor Litoxetine was used as the starting point in the design of a range of potential SSRIs with high ease of synthetic accessibility. Preparation and subsequent optimization yielded a range of potent and highly selective SSRIs.</description><identifier>ISSN: 0960-894X</identifier><identifier>EISSN: 1464-3405</identifier><identifier>DOI: 10.1016/j.bmcl.2009.02.054</identifier><identifier>PMID: 19282174</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ltd</publisher><subject>Biological and medical sciences ; Cell Line ; Drug Design ; Humans ; Medical sciences ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Pharmacology. Drug treatments ; Piperidines - chemical synthesis ; Piperidines - metabolism ; Re-uptake ; Seretonin ; Serotonin Uptake Inhibitors - chemical synthesis ; Serotonin Uptake Inhibitors - metabolism ; Serotoninergic system ; Structure-Activity Relationship ; Transporter</subject><ispartof>Bioorganic & medicinal chemistry letters, 2009-04, Vol.19 (8), p.2329-2332</ispartof><rights>2009 Elsevier Ltd</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-a2d15162d695aa7606158d09d3c8b71244e53efa2446de4242fe0ec82497ab693</citedby><cites>FETCH-LOGICAL-c415t-a2d15162d695aa7606158d09d3c8b71244e53efa2446de4242fe0ec82497ab693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21391812$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19282174$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Andrews, Mark</creatorcontrib><creatorcontrib>Brown, Alan</creatorcontrib><creatorcontrib>Chiva, Jean-Yves</creatorcontrib><creatorcontrib>Fradet, David</creatorcontrib><creatorcontrib>Gordon, David</creatorcontrib><creatorcontrib>Lansdell, Mark</creatorcontrib><creatorcontrib>MacKenny, Malcolm</creatorcontrib><title>Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility Part 1</title><title>Bioorganic & medicinal chemistry letters</title><addtitle>Bioorg Med Chem Lett</addtitle><description>The reported selective serotonin Re-uptake Inhibitor (SSRI) litoxetine was used as the starting point in the design of a range of potent, selective SSRIs with high ease of synthetic accessibility.
The reported selective serotonin Re-uptake Inhibitor Litoxetine was used as the starting point in the design of a range of potential SSRIs with high ease of synthetic accessibility. Preparation and subsequent optimization yielded a range of potent and highly selective SSRIs.</description><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Drug Design</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - chemical synthesis</subject><subject>Piperidines - metabolism</subject><subject>Re-uptake</subject><subject>Seretonin</subject><subject>Serotonin Uptake Inhibitors - chemical synthesis</subject><subject>Serotonin Uptake Inhibitors - metabolism</subject><subject>Serotoninergic system</subject><subject>Structure-Activity Relationship</subject><subject>Transporter</subject><issn>0960-894X</issn><issn>1464-3405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFkbGO1DAQhi0E4vYOXoACuYEuweM4TiLRoIMDpJOgAInOcpzJZZYkXmzvoeXp8WpX0EE1f_HNaPR_jD0DUYIA_Wpb9oubSylEVwpZilo9YBtQWhWVEvVDthGdFkXbqW8X7DLGrRCghFKP2QV0spXQqA2b32Kku5XbdeB-l2ihXzaRX7kfecQZXaJ7zCn45FdaecBiv0v2O3JaJ-op-RD5T0oTn-hu4vGwpgkTOW6dwxgzMVM68M82JA5P2KPRzhGfnucV-3rz7sv1h-L20_uP129uC6egToWVA9Sg5aC72tpGCw11O4huqFzbNyCVwrrC0eagB1RSyREFulaqrrG97qor9vJ0dxf8jz3GZBaKDufZruj30egGAFRb_xeUoq6gEZBBeQJd8DEGHM0u0GLDwYAwRxlma44yzFGGEdJkGXnp-fn6vl9w-Ltybj8DL86Ajc7OY7Cro_iHk1B10ILM3OsTh7m0e8JgoiNcHQ4UsiEzePrXH78BRzqoyg</recordid><startdate>20090415</startdate><enddate>20090415</enddate><creator>Andrews, Mark</creator><creator>Brown, Alan</creator><creator>Chiva, Jean-Yves</creator><creator>Fradet, David</creator><creator>Gordon, David</creator><creator>Lansdell, Mark</creator><creator>MacKenny, Malcolm</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20090415</creationdate><title>Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility Part 1</title><author>Andrews, Mark ; Brown, Alan ; Chiva, Jean-Yves ; Fradet, David ; Gordon, David ; Lansdell, Mark ; MacKenny, Malcolm</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-a2d15162d695aa7606158d09d3c8b71244e53efa2446de4242fe0ec82497ab693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Drug Design</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - chemical synthesis</topic><topic>Piperidines - metabolism</topic><topic>Re-uptake</topic><topic>Seretonin</topic><topic>Serotonin Uptake Inhibitors - chemical synthesis</topic><topic>Serotonin Uptake Inhibitors - metabolism</topic><topic>Serotoninergic system</topic><topic>Structure-Activity Relationship</topic><topic>Transporter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Andrews, Mark</creatorcontrib><creatorcontrib>Brown, Alan</creatorcontrib><creatorcontrib>Chiva, Jean-Yves</creatorcontrib><creatorcontrib>Fradet, David</creatorcontrib><creatorcontrib>Gordon, David</creatorcontrib><creatorcontrib>Lansdell, Mark</creatorcontrib><creatorcontrib>MacKenny, Malcolm</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic & medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Andrews, Mark</au><au>Brown, Alan</au><au>Chiva, Jean-Yves</au><au>Fradet, David</au><au>Gordon, David</au><au>Lansdell, Mark</au><au>MacKenny, Malcolm</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility Part 1</atitle><jtitle>Bioorganic & medicinal chemistry letters</jtitle><addtitle>Bioorg Med Chem Lett</addtitle><date>2009-04-15</date><risdate>2009</risdate><volume>19</volume><issue>8</issue><spage>2329</spage><epage>2332</epage><pages>2329-2332</pages><issn>0960-894X</issn><eissn>1464-3405</eissn><abstract>The reported selective serotonin Re-uptake Inhibitor (SSRI) litoxetine was used as the starting point in the design of a range of potent, selective SSRIs with high ease of synthetic accessibility.
The reported selective serotonin Re-uptake Inhibitor Litoxetine was used as the starting point in the design of a range of potential SSRIs with high ease of synthetic accessibility. Preparation and subsequent optimization yielded a range of potent and highly selective SSRIs.</abstract><cop>Amsterdam</cop><pub>Elsevier Ltd</pub><pmid>19282174</pmid><doi>10.1016/j.bmcl.2009.02.054</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-894X |
| ispartof | Bioorganic & medicinal chemistry letters, 2009-04, Vol.19 (8), p.2329-2332 |
| issn | 0960-894X 1464-3405 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67111485 |
| source | Elsevier |
| subjects | Biological and medical sciences Cell Line Drug Design Humans Medical sciences Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Pharmacology. Drug treatments Piperidines - chemical synthesis Piperidines - metabolism Re-uptake Seretonin Serotonin Uptake Inhibitors - chemical synthesis Serotonin Uptake Inhibitors - metabolism Serotoninergic system Structure-Activity Relationship Transporter |
| title | Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility Part 1 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T01%3A53%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design%20and%20optimization%20of%20selective%20serotonin%20re-uptake%20inhibitors%20with%20high%20synthetic%20accessibility%20Part%201&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry%20letters&rft.au=Andrews,%20Mark&rft.date=2009-04-15&rft.volume=19&rft.issue=8&rft.spage=2329&rft.epage=2332&rft.pages=2329-2332&rft.issn=0960-894X&rft.eissn=1464-3405&rft_id=info:doi/10.1016/j.bmcl.2009.02.054&rft_dat=%3Cproquest_cross%3E20531701%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c415t-a2d15162d695aa7606158d09d3c8b71244e53efa2446de4242fe0ec82497ab693%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20531701&rft_id=info:pmid/19282174&rfr_iscdi=true |